U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07122102) titled 'Safety and Efficacy Evaluation of Cofrogliptin (HSK7653) and Acarbose Research Among T2DMs' on Aug. 07.
Brief Summary: This study will compare the effect and safety of cofrogliptin (HSK7653) with acarbose among people with type 2 diabetes
Study Start Date: Sept. 01
Study Type: INTERVENTIONAL
Condition:
Type 2 Diabetes
Intervention:
DRUG: Cofrogliptin
10mg administered once every two weeks
DRUG: Acarbose
50mg administered 3 times daily
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Haisco Pharmaceutical Group Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....